Skip to main content
. 2022 May 24:1–10. Online ahead of print. doi: 10.1007/s10238-022-00836-x

Fig. 2.

Fig. 2

Complications of hyperviscosity in COVID-19: Hyperviscosity (HVS) in COVID-19 induces the development of endothelial dysfunction, microangiopathy, and hypoperfusion with the development of thrombosis and tissue hypoxia, which ultimately cause organ dysfunction